Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Aniridia - ptosis - intellectual disability - familial obesity is an extremely rare syndrome described in three members of a family (a mother and her two children) that is characterized by the association of various ocular abnormalities (partial or complete aniridia, ptosis, pendular nystagmus, corneal pannus, persistent pupillary membrane, lenticular opacities, foveal hypoplasia, and low visual acuity) with various systemic anomalies including intellectual disability and obesity in the two children, and alopecia, cardiac abnormalities, and frequent spontaneous abortion in the mother. There have been no further descriptions in the literature since 1986.
Biomarker and diagnostic research for aniridia-ptosis-intellectual disability-familial obesity syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
200 publications have been identified in PubMed for aniridia-ptosis-intellectual disability-familial obesity syndrome. Kisho has analyzed 137 by research type. Research spans Review / Meta-Analysis (47%), Basic Science / Preclinical (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 64 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 9:35 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
47%
Laboratory research | 25 | 18% |
Disease patterns and progression | 24 | 18% |
Clinical study results | 13 | 9% |
Patient case studies | 5 | 4% |
Testing and diagnosis research | 3 | 2% |
New treatment approaches | 3 | 2% |
Liu M (2026). [PMID: 41109537](https://pubmed.ncbi.nlm.nih.gov/41109537/). *J Ethnopharmacol*. [Basic Science / Preclinical]
Montagnana M (2026). [PMID: 41718117](https://pubmed.ncbi.nlm.nih.gov/41718117/). *Med Sci (Basel)*. [Review / Meta-Analysis]
Dutta D (2026). [PMID: 41741118](https://pubmed.ncbi.nlm.nih.gov/41741118/). *BMJ Case Rep*. [Case Report / Case Series]
Gad H (2026). [PMID: 42074171](https://pubmed.ncbi.nlm.nih.gov/42074171/). *Int J Mol Sci*. [Review / Meta-Analysis]
Panchpuri M (2026). [PMID: 41615570](https://pubmed.ncbi.nlm.nih.gov/41615570/). *Inflammopharmacology*. [Review / Meta-Analysis]
Gamero-de-Luna EJ (2026). [PMID: 41643274](https://pubmed.ncbi.nlm.nih.gov/41643274/). *Semergen*. [Review / Meta-Analysis]
Jena S (2026). [PMID: 41736347](https://pubmed.ncbi.nlm.nih.gov/41736347/). *J Pak Med Assoc*. [Review / Meta-Analysis]
Tharayil SP (2025). [PMID: 40650016](https://pubmed.ncbi.nlm.nih.gov/40650016/). *Int J Mol Sci*. [Review / Meta-Analysis]
Chen Y (2025). [PMID: 40751146](https://pubmed.ncbi.nlm.nih.gov/40751146/). *Cardiovasc Diabetol*. [Epidemiology / Natural History]
Ariadel-Cobo DG (2025). [PMID: 40076542](https://pubmed.ncbi.nlm.nih.gov/40076542/). *Int J Mol Sci*. [Review / Meta-Analysis]